Clinical Trial Update: WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating WGc-0201 in combination with tislelizumab for hepatocellular carcinoma at high risk of recurrence after radical thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• WGc-0201

Snippet

Sponsor: West China Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1 | Status: NOT_YET_RECRUITING